Welcome to our dedicated page for KRTL HOLDING GROUP news (Ticker: KRTL), a resource for investors and traders seeking the latest updates and insights on KRTL HOLDING GROUP stock.
KRTL Holding Group Inc. (OTC: KRTL) generates news across pharmaceuticals, biotechnology, APIs, cosmetics, consumer health, and neurotechnology. Its announcements highlight developments involving subsidiaries such as KRTL Biotech Inc., KRTL International Corp., Nutrivance Global, Neurogen Brain Balancing, and Bolivian pharmaceutical manufacturer SIGMA.
Readers of KRTL (KRTL) news can follow updates on pharmaceutical manufacturing and regulatory milestones, including the completion of PCAOB-audited financial statements, FDA Federal Establishment Identifier registration for SIGMA, and initiatives related to SEC Rule 15c2-11 compliance. News items also cover strategic transactions, such as KRTL Biotech’s merger with SIGMA, the acquisition of Neurogen Brain Balancing, and the majority stake in Nutrivance Global.
The company’s news flow includes product-focused announcements, such as the expansion of anti-infective and antibiotic portfolios manufactured at SIGMA’s GMP-certified facility in Bolivia, and the positioning of ELIXIR, a high-performance electrolyte hydration beverage, as a key consumer health product in the Bolivian market. Updates may describe how these products align with essential medicines lists, public health programs, and plans for international market entry, subject to regulatory pathways.
In addition, KRTL Holding Group Inc. issues news on joint ventures and international expansion, including its collaboration with Centro de Investigaciones Químicas - CIQ S.R.L. for sustainable API extraction, research, and manufacturing in Bolivia. Coverage may also address infrastructure projects, land-related initiatives, and cross-border trade frameworks that support pharmaceutical and cosmetic exports.
Investors, analysts, and industry observers can use the KRTL news page to track corporate actions, regulatory progress, product portfolio developments, and strategic partnerships that shape the company’s evolving role in global healthcare and wellness markets.
KRTL Holding Group's subsidiary, KRTL Biotech, has successfully registered SIGMACORP with the FDA as a U.S. pharmaceutical manufacturer. Acting as SIGMACORP's U.S. Registered Agent, KRTL Biotech aims to facilitate international pharmaceutical integration and diversify the U.S. healthcare supply chain.
This registration enables SIGMACORP to manufacture pharmaceutical products for the U.S. market, potentially introducing more affordable healthcare solutions. The partnership focuses on expanding market opportunities, enhancing competitive advantages, and supporting U.S. healthcare resilience through supply chain diversification.
The milestone strengthens U.S.-Bolivia relations in the healthcare sector and positions KRTL Biotech as a leader in international pharmaceutical collaboration.
KRTL Biotech, a subsidiary of KRTL Holding Group (OTC: KRTL), has achieved FDA registration, marking a strategic milestone in strengthening the U.S. pharmaceutical supply chain. The registration positions KRTL to facilitate international manufacturers' entry into the U.S. market, focusing on delivering high-quality active pharmaceutical ingredients (APIs) and finished products. The company plans to establish a manufacturing and distribution facility in 2025 to support both domestic and international partners. This initiative aims to provide lower-cost alternatives and optimized logistics solutions, enhancing supply chain stability while generating cost savings for the healthcare sector.
Summary not available.
Summary not available.
KRTL Holding Group, Inc. (OTC: KRTL) has announced a memorandum of understanding (MOU) with Yuhan Care, a subsidiary of the esteemed Yuhan Corporation. This collaboration focuses on developing CBD and cannabinoid-based products aimed at both the US and Korean markets. The agreement leverages KRTL’s established manufacturing partners and Yuhan’s expertise in cannabinoid research, promising high-quality products. Both companies aim to enhance their global footprint in the cannabis industry, with Yuhan being the first representative of CBD research in Korea's Hemp Free Zone.
KRTL Holding Group has welcomed Mr. David Beling as a Strategic Advisor, bringing over 50 years of mining experience. A graduate in Mining Engineering, Beling has contributed to various mining projects and companies, including Bullfrog Gold Corp and Geovic Mining Corp. His extensive background includes overseeing the development of significant mining operations and raising substantial capital. Beling expressed enthusiasm about enhancing KRTL's business model and production plans, indicating a promise for growth and profitability.
KRTL International Corp. (OTC: KRTL) has formed a strategic alliance with Cannabis Global, Inc. (OTC: CBGL) to enhance infusion technologies in the hemp and cannabis markets. This collaboration aims to develop water-soluble formulations and proprietary delivery methods for a variety of products. The partnership intends to leverage shared R&D and marketing strategies, allowing both companies to potentially access international markets, particularly in Asia. KRTL plans to showcase these innovations at the MJ BIZ CON event in November 2022.
KRTL International Corp. has partnered with ICANN Ventures and Yeungnam University to enhance the Korean Cannabis industry through professional education. The collaboration will launch a CBD Training Academy offering specialized courses and certification programs, starting October 2022. This initiative aims to educate a diverse group of professionals within the cannabis sector, responding to the evolving landscape in South Korea where medical cannabis use is becoming more accepted. The program emphasizes sustainable growth and aims to equip students with in-depth knowledge in the cannabis ecosystem.
KRTL Holding Group (OTC: KRTL) announced a strategic alliance with ENTEXS Corporation, focusing on advanced extraction technology for cannabis and psilocybin. They will showcase their mobile extraction unit at MJBizCon Las Vegas in November 2022. The partnership includes R&D support for psilocybin extraction and plans to introduce psilocybin products in Oregon's newly legalized market in early 2023. KRTL is also advancing cannabis technology in South Korea, specifically THC remediation, with a focus on maintaining CBD concentrations while retaining regulatory compliance.
KRTL Holding Group, Inc. (OTC: KRTL) announced a strategic alliance with Entexs Corporation and Iron Sight Industries to deploy a mobile extraction plant for cannabis and hemp. This state-of-the-art system can extract up to 2,000 pounds of biomass per day and is engineered for remote operation. KRTL aims to launch operations in several states, tapping into a potential annual market of over $200 million from THC distillate and isolate production. The collaboration enhances KRTL's operational flexibility and stakeholder risk management.